Labcorp Unveils AI Platform with AWS to Slash Alzheimer’s Research Timelines
Labcorp launched an AI-powered real-world data platform with AWS and Datavant to accelerate Alzheimer’s drug research by reducing data preparation from months to minutes. The platform leverages deidentified lab and genomic datasets from millions of patients and advanced analytics to streamline patient cohort identification and boost trial recruitment.
1. AI-Powered Real-World Data Platform
Labcorp’s new platform uses agentic AI and standardized direct-from-source laboratory data to transform Alzheimer’s research workflows. By integrating advanced analytics, it compresses months of manual data preparation into minutes, enabling rapid hypothesis testing and faster insight generation.
2. Strategic Partnership with AWS and Datavant
Developed in collaboration with AWS and Datavant, the platform leverages Amazon Bedrock agents and SageMaker for AI model training, while using Datavant’s privacy-preserving connectivity to secure deidentified healthcare datasets. This integration ensures scalable, compliant access to diverse data streams.
3. Impact on Alzheimer’s Research and Clinical Trials
With over 7.2 million Americans living with Alzheimer’s and U.S. care costs exceeding $380 billion annually, accelerated data analysis can shorten drug development timelines and improve patient cohort identification. The platform’s analytics interface supports real-time treatment pattern analysis and targeted trial recruitment.
4. Future Expansion and Broader Applications
Initial validation is expected to complete in spring 2026, with plans to add electronic health record data and social determinants of health later this year. Beyond neurology, Labcorp intends to extend the platform’s AI analytics to inflammatory diseases, cardiometabolic conditions, women’s health and oncology.